Activity of the Antiseptic Polyhexanide Against Gram-Negative Bacteria
The activity of the antiseptic polyhexanide was tested against 250 gram-negative clinical isolates, that is, 50 isolates each of Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Moraxella catarrhalis , and Haemophilus influenzae . Minimal inhibitory concentrations (MICs) and minim...
Gespeichert in:
Veröffentlicht in: | Microbial drug resistance (Larchmont, N.Y.) N.Y.), 2014-04, Vol.20 (2), p.138-143 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 143 |
---|---|
container_issue | 2 |
container_start_page | 138 |
container_title | Microbial drug resistance (Larchmont, N.Y.) |
container_volume | 20 |
creator | Fabry, Werner Hugo Karl Kock, Hans-Jürgen Vahlensieck, Winfried |
description | The activity of the antiseptic polyhexanide was tested against 250 gram-negative clinical isolates, that is, 50 isolates each of
Escherichia coli
,
Klebsiella pneumoniae
,
Pseudomonas aeruginosa
,
Moraxella catarrhalis
, and
Haemophilus influenzae
. Minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) were determined by using a serial broth microdilution technique according to DIN 58940. Time-kill studies were performed for reference stains
E. coli
ATCC 25922,
K. pneumoniae
ATCC 4352,
P. aeruginosa
ATCC 15442,
M. catarrhalis
ATCC 43617, and
H. influenzae
ATCC 49247. All tested isolates had MICs and MBCs within a range of 1–32 mg/L and were regarded as susceptible to polyhexanide. The highest values were found for
P. aeruginosa
and
H. influenzae
with MICs and MBCs of 32 mg/L. Addition of up to 4% albumin to the test medium did not change MICs and MBCs. Time-kill studies of the reference strains showed reduction rates from 3 log
10
colony forming units (CFU)/ml to more than 5 log
10
CFU/ml for 200 and 400 mg/L polyhexanide within 5–30 min. Testing of polyhexanide in combination with antibiotics showed indifference with amoxicillin, cefotaxime, imipenem, gentamicin, and ciprofloxacin; no antagonism was found. As no resistance and no antagonism with antibiotics were detected, polyhexanide is regarded as suitable agent for topical eradication of gram-negative bacteria. |
doi_str_mv | 10.1089/mdr.2013.0113 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1516739427</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1516739427</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-4e581827f5877007266d7beec0c79a06a756f6e51b004f7fc449963d3431f9ec3</originalsourceid><addsrcrecordid>eNqN0T1PwzAQBmALgWgpjKwoEgtLyjl27HgsFV9SBQwwR65zAVf5KLaL6L_HVQsDC0y2Ts-ddPcSckphTKFQl23lxhlQNgZK2R4ZUsVoWnBe7Mc_SJGKTPEBOfJ-AQA5FeyQDDJOVcaUHJKbiQn2w4Z10tdJeMNk0gXrcRmsSZ76Zv2Gn7qzVay_atv5kNw63aYP-KpjGyZX2gR0Vh-Tg1o3Hk9274i83Fw_T-_S2ePt_XQySw1TRUg55gUtMlnnhZQAMhOiknNEA0YqDULLXNQCczoH4LWsDedKCVYxzmit0LARudjOXbr-fYU-lK31BptGd9ivfEnjgpIpnsn_UADFuMgiPf9FF_3KdXGRqEDFMzJRRJVulXG99w7rculsq926pFBusihjFuUmi3KTRfRnu6mreYvVj_4-fgRsCzZl3XWNxTm68MfYL0Hdky8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1509107368</pqid></control><display><type>article</type><title>Activity of the Antiseptic Polyhexanide Against Gram-Negative Bacteria</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Fabry, Werner Hugo Karl ; Kock, Hans-Jürgen ; Vahlensieck, Winfried</creator><creatorcontrib>Fabry, Werner Hugo Karl ; Kock, Hans-Jürgen ; Vahlensieck, Winfried</creatorcontrib><description>The activity of the antiseptic polyhexanide was tested against 250 gram-negative clinical isolates, that is, 50 isolates each of
Escherichia coli
,
Klebsiella pneumoniae
,
Pseudomonas aeruginosa
,
Moraxella catarrhalis
, and
Haemophilus influenzae
. Minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) were determined by using a serial broth microdilution technique according to DIN 58940. Time-kill studies were performed for reference stains
E. coli
ATCC 25922,
K. pneumoniae
ATCC 4352,
P. aeruginosa
ATCC 15442,
M. catarrhalis
ATCC 43617, and
H. influenzae
ATCC 49247. All tested isolates had MICs and MBCs within a range of 1–32 mg/L and were regarded as susceptible to polyhexanide. The highest values were found for
P. aeruginosa
and
H. influenzae
with MICs and MBCs of 32 mg/L. Addition of up to 4% albumin to the test medium did not change MICs and MBCs. Time-kill studies of the reference strains showed reduction rates from 3 log
10
colony forming units (CFU)/ml to more than 5 log
10
CFU/ml for 200 and 400 mg/L polyhexanide within 5–30 min. Testing of polyhexanide in combination with antibiotics showed indifference with amoxicillin, cefotaxime, imipenem, gentamicin, and ciprofloxacin; no antagonism was found. As no resistance and no antagonism with antibiotics were detected, polyhexanide is regarded as suitable agent for topical eradication of gram-negative bacteria.</description><identifier>ISSN: 1076-6294</identifier><identifier>EISSN: 1931-8448</identifier><identifier>DOI: 10.1089/mdr.2013.0113</identifier><identifier>PMID: 24192397</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>Anti-Bacterial Agents - pharmacology ; Anti-Infective Agents, Local - pharmacology ; Antibiotics ; Bacteria ; Bacterial infections ; beta-Lactams - pharmacology ; Biguanides - pharmacology ; Ciprofloxacin - pharmacology ; Drug Combinations ; Drug resistance ; E coli ; Epidemiology ; Escherichia coli ; Escherichia coli - drug effects ; Escherichia coli - growth & development ; Gentamicins - pharmacology ; Gram-negative bacteria ; Haemophilus influenzae ; Haemophilus influenzae - drug effects ; Haemophilus influenzae - growth & development ; Klebsiella pneumoniae ; Klebsiella pneumoniae - drug effects ; Klebsiella pneumoniae - growth & development ; Microbial Sensitivity Tests ; Microbial Viability - drug effects ; Microbiology ; Moraxella (Branhamella) catarrhalis - drug effects ; Moraxella (Branhamella) catarrhalis - growth & development ; Moraxella catarrhalis ; Pseudomonas aeruginosa ; Pseudomonas aeruginosa - drug effects ; Pseudomonas aeruginosa - growth & development</subject><ispartof>Microbial drug resistance (Larchmont, N.Y.), 2014-04, Vol.20 (2), p.138-143</ispartof><rights>2014, Mary Ann Liebert, Inc.</rights><rights>(©) Copyright 2014, Mary Ann Liebert, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-4e581827f5877007266d7beec0c79a06a756f6e51b004f7fc449963d3431f9ec3</citedby><cites>FETCH-LOGICAL-c398t-4e581827f5877007266d7beec0c79a06a756f6e51b004f7fc449963d3431f9ec3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24192397$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fabry, Werner Hugo Karl</creatorcontrib><creatorcontrib>Kock, Hans-Jürgen</creatorcontrib><creatorcontrib>Vahlensieck, Winfried</creatorcontrib><title>Activity of the Antiseptic Polyhexanide Against Gram-Negative Bacteria</title><title>Microbial drug resistance (Larchmont, N.Y.)</title><addtitle>Microb Drug Resist</addtitle><description>The activity of the antiseptic polyhexanide was tested against 250 gram-negative clinical isolates, that is, 50 isolates each of
Escherichia coli
,
Klebsiella pneumoniae
,
Pseudomonas aeruginosa
,
Moraxella catarrhalis
, and
Haemophilus influenzae
. Minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) were determined by using a serial broth microdilution technique according to DIN 58940. Time-kill studies were performed for reference stains
E. coli
ATCC 25922,
K. pneumoniae
ATCC 4352,
P. aeruginosa
ATCC 15442,
M. catarrhalis
ATCC 43617, and
H. influenzae
ATCC 49247. All tested isolates had MICs and MBCs within a range of 1–32 mg/L and were regarded as susceptible to polyhexanide. The highest values were found for
P. aeruginosa
and
H. influenzae
with MICs and MBCs of 32 mg/L. Addition of up to 4% albumin to the test medium did not change MICs and MBCs. Time-kill studies of the reference strains showed reduction rates from 3 log
10
colony forming units (CFU)/ml to more than 5 log
10
CFU/ml for 200 and 400 mg/L polyhexanide within 5–30 min. Testing of polyhexanide in combination with antibiotics showed indifference with amoxicillin, cefotaxime, imipenem, gentamicin, and ciprofloxacin; no antagonism was found. As no resistance and no antagonism with antibiotics were detected, polyhexanide is regarded as suitable agent for topical eradication of gram-negative bacteria.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Infective Agents, Local - pharmacology</subject><subject>Antibiotics</subject><subject>Bacteria</subject><subject>Bacterial infections</subject><subject>beta-Lactams - pharmacology</subject><subject>Biguanides - pharmacology</subject><subject>Ciprofloxacin - pharmacology</subject><subject>Drug Combinations</subject><subject>Drug resistance</subject><subject>E coli</subject><subject>Epidemiology</subject><subject>Escherichia coli</subject><subject>Escherichia coli - drug effects</subject><subject>Escherichia coli - growth & development</subject><subject>Gentamicins - pharmacology</subject><subject>Gram-negative bacteria</subject><subject>Haemophilus influenzae</subject><subject>Haemophilus influenzae - drug effects</subject><subject>Haemophilus influenzae - growth & development</subject><subject>Klebsiella pneumoniae</subject><subject>Klebsiella pneumoniae - drug effects</subject><subject>Klebsiella pneumoniae - growth & development</subject><subject>Microbial Sensitivity Tests</subject><subject>Microbial Viability - drug effects</subject><subject>Microbiology</subject><subject>Moraxella (Branhamella) catarrhalis - drug effects</subject><subject>Moraxella (Branhamella) catarrhalis - growth & development</subject><subject>Moraxella catarrhalis</subject><subject>Pseudomonas aeruginosa</subject><subject>Pseudomonas aeruginosa - drug effects</subject><subject>Pseudomonas aeruginosa - growth & development</subject><issn>1076-6294</issn><issn>1931-8448</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqN0T1PwzAQBmALgWgpjKwoEgtLyjl27HgsFV9SBQwwR65zAVf5KLaL6L_HVQsDC0y2Ts-ddPcSckphTKFQl23lxhlQNgZK2R4ZUsVoWnBe7Mc_SJGKTPEBOfJ-AQA5FeyQDDJOVcaUHJKbiQn2w4Z10tdJeMNk0gXrcRmsSZ76Zv2Gn7qzVay_atv5kNw63aYP-KpjGyZX2gR0Vh-Tg1o3Hk9274i83Fw_T-_S2ePt_XQySw1TRUg55gUtMlnnhZQAMhOiknNEA0YqDULLXNQCczoH4LWsDedKCVYxzmit0LARudjOXbr-fYU-lK31BptGd9ivfEnjgpIpnsn_UADFuMgiPf9FF_3KdXGRqEDFMzJRRJVulXG99w7rculsq926pFBusihjFuUmi3KTRfRnu6mreYvVj_4-fgRsCzZl3XWNxTm68MfYL0Hdky8</recordid><startdate>20140401</startdate><enddate>20140401</enddate><creator>Fabry, Werner Hugo Karl</creator><creator>Kock, Hans-Jürgen</creator><creator>Vahlensieck, Winfried</creator><general>Mary Ann Liebert, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7T7</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20140401</creationdate><title>Activity of the Antiseptic Polyhexanide Against Gram-Negative Bacteria</title><author>Fabry, Werner Hugo Karl ; Kock, Hans-Jürgen ; Vahlensieck, Winfried</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-4e581827f5877007266d7beec0c79a06a756f6e51b004f7fc449963d3431f9ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Infective Agents, Local - pharmacology</topic><topic>Antibiotics</topic><topic>Bacteria</topic><topic>Bacterial infections</topic><topic>beta-Lactams - pharmacology</topic><topic>Biguanides - pharmacology</topic><topic>Ciprofloxacin - pharmacology</topic><topic>Drug Combinations</topic><topic>Drug resistance</topic><topic>E coli</topic><topic>Epidemiology</topic><topic>Escherichia coli</topic><topic>Escherichia coli - drug effects</topic><topic>Escherichia coli - growth & development</topic><topic>Gentamicins - pharmacology</topic><topic>Gram-negative bacteria</topic><topic>Haemophilus influenzae</topic><topic>Haemophilus influenzae - drug effects</topic><topic>Haemophilus influenzae - growth & development</topic><topic>Klebsiella pneumoniae</topic><topic>Klebsiella pneumoniae - drug effects</topic><topic>Klebsiella pneumoniae - growth & development</topic><topic>Microbial Sensitivity Tests</topic><topic>Microbial Viability - drug effects</topic><topic>Microbiology</topic><topic>Moraxella (Branhamella) catarrhalis - drug effects</topic><topic>Moraxella (Branhamella) catarrhalis - growth & development</topic><topic>Moraxella catarrhalis</topic><topic>Pseudomonas aeruginosa</topic><topic>Pseudomonas aeruginosa - drug effects</topic><topic>Pseudomonas aeruginosa - growth & development</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fabry, Werner Hugo Karl</creatorcontrib><creatorcontrib>Kock, Hans-Jürgen</creatorcontrib><creatorcontrib>Vahlensieck, Winfried</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Microbial drug resistance (Larchmont, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fabry, Werner Hugo Karl</au><au>Kock, Hans-Jürgen</au><au>Vahlensieck, Winfried</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Activity of the Antiseptic Polyhexanide Against Gram-Negative Bacteria</atitle><jtitle>Microbial drug resistance (Larchmont, N.Y.)</jtitle><addtitle>Microb Drug Resist</addtitle><date>2014-04-01</date><risdate>2014</risdate><volume>20</volume><issue>2</issue><spage>138</spage><epage>143</epage><pages>138-143</pages><issn>1076-6294</issn><eissn>1931-8448</eissn><abstract>The activity of the antiseptic polyhexanide was tested against 250 gram-negative clinical isolates, that is, 50 isolates each of
Escherichia coli
,
Klebsiella pneumoniae
,
Pseudomonas aeruginosa
,
Moraxella catarrhalis
, and
Haemophilus influenzae
. Minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) were determined by using a serial broth microdilution technique according to DIN 58940. Time-kill studies were performed for reference stains
E. coli
ATCC 25922,
K. pneumoniae
ATCC 4352,
P. aeruginosa
ATCC 15442,
M. catarrhalis
ATCC 43617, and
H. influenzae
ATCC 49247. All tested isolates had MICs and MBCs within a range of 1–32 mg/L and were regarded as susceptible to polyhexanide. The highest values were found for
P. aeruginosa
and
H. influenzae
with MICs and MBCs of 32 mg/L. Addition of up to 4% albumin to the test medium did not change MICs and MBCs. Time-kill studies of the reference strains showed reduction rates from 3 log
10
colony forming units (CFU)/ml to more than 5 log
10
CFU/ml for 200 and 400 mg/L polyhexanide within 5–30 min. Testing of polyhexanide in combination with antibiotics showed indifference with amoxicillin, cefotaxime, imipenem, gentamicin, and ciprofloxacin; no antagonism was found. As no resistance and no antagonism with antibiotics were detected, polyhexanide is regarded as suitable agent for topical eradication of gram-negative bacteria.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>24192397</pmid><doi>10.1089/mdr.2013.0113</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1076-6294 |
ispartof | Microbial drug resistance (Larchmont, N.Y.), 2014-04, Vol.20 (2), p.138-143 |
issn | 1076-6294 1931-8448 |
language | eng |
recordid | cdi_proquest_miscellaneous_1516739427 |
source | MEDLINE; Alma/SFX Local Collection |
subjects | Anti-Bacterial Agents - pharmacology Anti-Infective Agents, Local - pharmacology Antibiotics Bacteria Bacterial infections beta-Lactams - pharmacology Biguanides - pharmacology Ciprofloxacin - pharmacology Drug Combinations Drug resistance E coli Epidemiology Escherichia coli Escherichia coli - drug effects Escherichia coli - growth & development Gentamicins - pharmacology Gram-negative bacteria Haemophilus influenzae Haemophilus influenzae - drug effects Haemophilus influenzae - growth & development Klebsiella pneumoniae Klebsiella pneumoniae - drug effects Klebsiella pneumoniae - growth & development Microbial Sensitivity Tests Microbial Viability - drug effects Microbiology Moraxella (Branhamella) catarrhalis - drug effects Moraxella (Branhamella) catarrhalis - growth & development Moraxella catarrhalis Pseudomonas aeruginosa Pseudomonas aeruginosa - drug effects Pseudomonas aeruginosa - growth & development |
title | Activity of the Antiseptic Polyhexanide Against Gram-Negative Bacteria |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T10%3A43%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Activity%20of%20the%20Antiseptic%20Polyhexanide%20Against%20Gram-Negative%20Bacteria&rft.jtitle=Microbial%20drug%20resistance%20(Larchmont,%20N.Y.)&rft.au=Fabry,%20Werner%20Hugo%20Karl&rft.date=2014-04-01&rft.volume=20&rft.issue=2&rft.spage=138&rft.epage=143&rft.pages=138-143&rft.issn=1076-6294&rft.eissn=1931-8448&rft_id=info:doi/10.1089/mdr.2013.0113&rft_dat=%3Cproquest_cross%3E1516739427%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1509107368&rft_id=info:pmid/24192397&rfr_iscdi=true |